Belgian Biotech Stock News

Anheuser-Busch InBev (ENXTBR:ABI) stock is in focus after the company committed more than $20 million to its Missouri operations and confirmed Dirk Van de Put as its incoming Chairman. See our latest analysis for Anheuser-Busch InBev. The recent announcement of over €20 million in Missouri investments and the confirmation of Dirk Van de Put as incoming Chairman come after a strong run, with Anheuser-Busch InBev’s year to date share price return of 30.22% and a 5 year total shareholder return...

Cenergy Holdings SA ( EBR:CENER ), is not the largest company out there, but it received a lot of attention from a...

Cmb.Tech (ENXTBR:CMBT) is in focus after its latest financial score of 7.93 highlighted what appears to be solid operating efficiency, with reported year-over-year gains in both revenue and net profit. See our latest analysis for Cmb.Tech. Despite the recent pullback, with the 1-day share price return down 4.02% and the 30-day share price return down 14.81% to €12.42, Cmb.Tech still shows strong upward momentum overall, supported by a 90-day share price return of 15.43%, a 54.09% year to date...

The resignation of Frederik Vandepitte as CEO of Cera Group and KBC Ancora, key anchor shareholders controlling over 41% of KBC Group (ENXTBR:KBC), puts governance and long term shareholder influence in sharper focus for investors. See our latest analysis for KBC Group. KBC Group’s recent share price return paints a mixed picture, with the stock down 0.7% on the day to €119.05 but recording a 7.4% 7 day and 9.4% 30 day share price return, alongside a 1 year total shareholder return of 46.3%...

Sipef (ENXTBR:SIP) has drawn fresh attention after announcing an annual cash dividend of €3.01 per share, with an ex dividend date on 12 June 2026 and payment scheduled for 1 July 2026. See our latest analysis for Sipef. While Sipef’s share price has eased recently, with a 7.10% 30 day share price return and a 3.23% 7 day share price return both in decline, its 12.74% year to date share price return and 53.13% 1 year total shareholder return point to momentum that has built over a longer...

The European Patent Office has upheld Solvay (ENXTBR:SOLB)’s key European patent covering its soda ash purge stream recycling process after a challenge from WE Soda Ltd, putting the company’s intellectual property position firmly in focus for investors. See our latest analysis for Solvay. Solvay’s recent patent win comes at a time when the stock’s 7-day share price return of 5.98% and 30-day share price return of 4.12% sit against a 1-year total shareholder return that is down 3.84%, while...

European markets have shown mixed performance recently, as investors navigate the European Central Bank's interest rate hikes and ongoing geopolitical tensions. Despite these challenges, there remains a keen interest in exploring investment opportunities within smaller or newer companies that may offer significant growth potential. While the term "penny stocks" may seem outdated, it continues to capture the essence of investing in companies with lower market capitalizations that could present...

Texaf (ENXTBR:TEXF) has just posted its FY 2025 results with second half revenue of €17.7 million and basic EPS of €1.21, underpinned by trailing twelve month EPS of €2.45 and net income of €9.0 million. The company has seen revenue move from €16.8 million in the second half of 2024 to €17.7 million in the second half of 2025, while trailing twelve month revenue sits at €35.0 million against a backdrop of reported earnings growth of 21% over the last year. With net profit margin at 25.7%...

Earlier in June 2026, ELIQUENT Life Sciences announced that UCB went live with the full Veeva Safety Suite, consolidating its global pharmacovigilance operations into a single cloud-based platform delivered in collaboration with Veeva, Pinnaxis, and Daelight Solutions. Separately, UCB and Biogen presented Phase 3 PHOENYCS GO data at EULAR 2026 suggesting dapirolizumab pegol may help systemic lupus erythematosus patients sustain disease control while reducing long-term steroid exposure,...

argenx (ENXTBR:ARGX) has been in focus after the FDA expanded approval for its flagship drug Vyvgart to cover all adult patients with generalized myasthenia gravis, regardless of antibody status, drawing fresh attention to the stock. See our latest analysis for argenx. argenx’s recent FDA label expansion for Vyvgart and new rheumatology data have arrived alongside a 14.03% 1 month share price return and a 55.91% 1 year total shareholder return, indicating that momentum has been present over...

KBC Ancora (ENXTBR:KBCA) has drawn fresh attention after announcing an annual cash dividend of €3.024 per share, with an ex-dividend date set for 2 June 2026 and payment scheduled for 4 June. See our latest analysis for KBC Ancora. Recent trading reflects a mixed picture, with the share price at €76.9 after a 1 day gain of 1.05%, a 7 day decline of 5.64% and a 30 day fall of 3.15%. At the same time, the 1 year total shareholder return of 34.0% and 5 year total shareholder return of 180.25%...

Dividend announcement and what it means for investors D'Ieteren Group (ENXTBR:DIE) has declared an annual dividend of €1.40 per share, with an ex dividend date on 9 June 2026, record date on 10 June and payment on 11 June. This dividend decision puts income directly on the table for shareholders. It also offers a fresh data point on how management is choosing to return cash alongside the group’s investment focused business model. See our latest analysis for D'Ieteren Group. The dividend news...

Earlier this week, argenx SE reported new 52‑ and 72‑week data on VYVGART (efgartigimod) in myositis and Sjogren’s disease at the EULAR 2026 Congress, showing sustained clinical improvements and a consistent safety profile in both open‑label extension studies. The results reinforce the potential relevance of FcRn blockade across multiple autoimmune rheumatic conditions, suggesting VYVGART could address a broader pool of difficult‑to‑treat patients beyond its current indications. Next, we’ll...

Proximus (ENXTBR:PROX) and Unifiber SA recently held an M&A call indicating interest in a potential transaction. The discussion signals that both companies are assessing options for closer collaboration or corporate action. Details on structure, timing, and financial terms have not been made public. For investors watching Proximus at a share price of €6.61, the prospect of an M&A move with Unifiber SA comes after a mixed share price record. The stock is down 7.6% year to date and down 44.3%...

Recent performance snapshot for Ackermans & Van Haaren (ENXTBR:ACKB) Ackermans & Van Haaren (ENXTBR:ACKB) has drawn attention after a period where the stock is up 12.7% year to date, yet down 6.5% over the past month and 4.9% over the past 3 months. At a last close of €262.20 and a market value of about €8.57b, the company reports annual revenue of €5,961.61m and net income of €592.55m, with annual revenue growth of 2.18% and net income growth of 5.72%. See our latest analysis for Ackermans &...

Tessenderlo Group NV ( EBR:TESB ) stock is about to trade ex-dividend in three days. The ex-dividend date is two...

As European markets experience a positive momentum with the STOXX Europe 600 Index rising by 3.00%, optimism is fueled by hopes of easing geopolitical tensions in the Middle East. However, economic growth forecasts have been trimmed due to energy shocks and volatile trade environments, creating a landscape where identifying stocks potentially undervalued becomes crucial for investors seeking opportunities amidst uncertainty. In such conditions, a good stock might be one that demonstrates...

ageas SA/NV ( EBR:AGS ) is about to trade ex-dividend in the next four days. The ex-dividend date is two business days...

Payton Planar Magnetics (ENXTBR:PAY) has just posted Q1 2026 revenue of US$10.65 million with basic EPS of US$0.08. This sets the tone for how investors will read the latest numbers against a year in which trailing twelve month EPS was US$0.55 on revenue of US$46.83 million. Over recent quarters, revenue has ranged between US$9.61 million and US$13.23 million while quarterly basic EPS has moved between US$0.08 and US$0.20. This gives investors a clear view of how top line and per share...

Wondering if Umicore at €25.62 is offering genuine value or just catching your eye after a strong run? This article breaks down what the current price might be implying. The stock has recently returned 4.9% over 7 days, 50.2% over 30 days, 37.8% year to date, and 178.3% over 1 year, which naturally raises questions about how much of the story is already in the price. Recent coverage has focused on Umicore's position in materials and related technologies, with investors paying close attention...

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing by 3% amid hopes for geopolitical de-escalation, investors are increasingly seeking stable returns in an environment marked by adjusted growth forecasts and persistent inflation concerns. In such a climate, dividend stocks can offer an attractive option for generating income, as they provide regular payouts that can help offset market volatility and economic uncertainties.

EVS Broadcast Equipment SA ( EBR:EVS ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is commonly...

In the first quarter of 2026, Syensqo reported sales of €1,461 million, with net income improving to €62 million from a small loss a year earlier, and basic earnings per share rising to €0.60. Ahead of these results, the company launched a review of its Performance & Care segment to sharpen its focus on specialty materials and advanced technologies across sectors such as aerospace, electronics, healthcare, energy, and advanced mobility. We’ll now consider how the Performance & Care segment...

Cmb.Tech NV ( EBR:CMBT ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...